Compare MMLP & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | VRCA |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 88.0M |
| IPO Year | 2002 | 2018 |
| Metric | MMLP | VRCA |
|---|---|---|
| Price | $2.07 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.83 |
| AVG Volume (30 Days) | 25.6K | ★ 51.9K |
| Earning Date | 10-21-2026 | 11-13-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.65 | ★ 370.22 |
| 52 Week Low | $1.76 | $3.28 |
| 52 Week High | $3.24 | $9.82 |
| Indicator | MMLP | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 37.19 |
| Support Level | $1.83 | N/A |
| Resistance Level | $2.42 | $5.94 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 69.39 | 24.32 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.